3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
33
Breast Diseases
3
Neoplasms by Site
2
Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Ovarian Neoplasms
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HER2 Negative Breast Cancer
1
Endometrial Neoplasms
1
Carcinoma, Lobular
1
Carcinoma, Ductal, Breast
1
Breast Neoplasm Female
1
Breast Carcinoma In Situ
1
Anatomic Stage III Breast Cancer AJCC v8
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Breast Carcinoma
1
Interventions
Bevacizumab
35
Paclitaxel
31
Carboplatin
24
pembrolizumab
23
Specimen Handling
21
Magnetic Resonance Spectroscopy
19
Gemcitabine
18
olaparib
16
liposomal doxorubicin
16
Cyclophosphamide
15
fludarabine
12
Topotecan
12
Biopsy
12
niraparib
11
Cisplatin
10
Taxes
8
Nivolumab
8
Immunoglobulin G
8
Fulvestrant
8
Disulfides
8
Doxorubicin
7
aldesleukin
6
Surveys and Questionnaires
6
palbociclib
5
Oxaliplatin
5
Fluorouracil
5
trastuzumab deruxtecan
4
oregovomab
4
mirvetuximab soravtansine
4
X-Rays
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Anastrozole
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled